← Home
Roche Holding 
Pharma / Pharma
Press Releases
| Date | Press release |
|---|---|
| 2025-04-30 06:54:00 | Blood-based Biomarkers (bbb) Market Review 2023-2024 And Growth Opportunities 2025-2035 Featuring Profiles Of Key Players - Roche, Sysmex Corporation, Mirxes, Minomic, Creative Diagnostics And More Dublin, april 30, 2025 (globe newswire) -- the \"blood-based biomarker market - a global and regional analysis: focus on disease, application, and country-level analysis, 2025-2035\" report has been added to researchandmarkets.com’s offering. the global blood-based biomarker market is poised for substantial growth, driven by the increasing demand for non-invasive diagnostic techniques and advancements in biomarker discovery for diseases such as cancer, neurological disorders, and various others. |
| 2025-04-30 01:00:00 | Chmp Recommends Eu Label Update For Roche’s Phesgo To Allow Administration Outside Of Clinical Settings Basel, 30 april 2025 - roche (six: ro, rog; otcqx: rhhby) announced today that the european medicines agency’s committee for medicinal products for human use (chmp) has issued a positive opinion recommending an update to the european union (eu) label for phesgo®, a subcutaneous (sc) fixed-dose combination of perjeta® (pertuzumab) and herceptin® (trastuzumab), for human epidermal growth factor receptor 2 (her2)-positive breast cancer. if approved, administration of phesgo outside of a clinical setting (such as in a person’s home) by a healthcare professional will be possible, once safely established in a clinical setting. a final decision regarding the approval is expected from the european commission in the near future. |
| 2025-04-25 01:00:00 | New England Journal Of Medicine Publishes Phase Iii Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby) announced today that the new england journal of medicine (nejm) has published a detailed analysis of the phase iii centerstone trial of xofluza® (baloxavir marboxil). the trial met its primary endpoint, showing a single, oral dose of xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. for the key secondary end. |
| 2025-04-22 01:00:00 | Roche To Invest Usd 50 Billion In Pharmaceuticals And Diagnostics In The United States Over The Next Five Years Basel, 22 april 2025 - roche (six: ro, rog; otcqx: rhhby) announced today that it will invest usd 50 billion into the united states of america in the next five years. these investments further strengthen roche’s already significant us footprint with 13 manufacturing and 15 r&d sites across the pharmaceutical and diagnostics divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities. |
| 2025-04-15 08:00:00 | Oak Hill Bio Enters Into Exclusive License Agreement With Roche To Obtain Global Rights For A Phase 3-ready, Potential Best-in-class Treatment For Individuals With Angelman Syndrome Cambridge, mass.--(business wire)-- #biotech--oak hill bio has entered into an exclusive license agreement with roche to obtain global rights for rugonersen for angelman syndrome. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal